hotspot -WSS

hotspot

author：entertainment 2025-09-06 01:24:48 - browse：5

Adobe

LONDON — Merck said Wednesday it is buying ophthalmology-focused startup EyeBio in a deal worth up to $3 billion, as the pharma company looks to diversify its pipeline.

Under the deal, Merck, through a subsidiary, will pay $1.3 billion in cash upfront, with another $1.7 billion potentially included if certain regulatory and commercial milestones are met. The Wall Street Journal first reported the news Tuesday night.

EyeBio has been developing a drug called restoret for a number of retinal diseases, including age-related macular degeneration and diabetic macular edema. It presented data in February from a Phase 1/2 trial of restoret in both conditions. Merck said it plans to move restoret into a pivotal trial for diabetic macular edema later this year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： People can get long Covid without testing positive for virus: Study

WSS

As obesity drug market grows, telehealth companies court payers

California store owner shot dead in dispute over displaying Pride flag: Police

Abortion policy in the spotlight at Republican debate

Giant panda gives birth to squirming, squealing healthy twin girls at South Korean theme park

Wegovy improves function in certain heart failure patients

A Greenpeace activist is fined for crash

entertainment

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

How to save PrEP access — and even expand it

CDC says it’s too soon to assess risk posed by Covid subvariant

Moonlake's readout produced a cash windfall. Risks remain

How the first Native Hawaiian psychiatrist helped diversify medicine

Psychedelics group wrestles with new pharma identity

Wegovy improves function in certain heart failure patients

United colonoscopy coverage change 'may cost lives,' doctors say

Russia's threat to pull out of Ukraine grain deal raises fears about global food security

United colonoscopy coverage change 'may cost lives,' doctors say

Cuban government calls US nuclear submarine stop a 'provocative escalation'

leisure time

Digital health funding stays low as a new reality sets in

How to make over

How to make over

Grail's uphill battle for Medicare to cover its cancer screening test

Kellogg’s is going to war over Mexico’s nutrition label rules

Women's World Cup brings attention to abuse in soccer

knowledge

hotspot

leisure time

entertainment